Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1, First in Man, Multicenter, Open Label, Single Escalating Dose Study of BAY1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors

Next Previous
Search
Trial Profile

A Phase 1, First in Man, Multicenter, Open Label, Single Escalating Dose Study of BAY1093884 in Subjects With Severe Hemophilia Types A or B, With or Without Inhibitors

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 10 Dec 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Befovacimab (Primary) ; Befovacimab (Primary)
  • Indications Haemophilia A; Haemophilia B
  • Focus Adverse reactions; First in man; Pharmacodynamics; Pharmacokinetics
  • Sponsors Bayer

    • Most Recent Events

    • 04 Dec 2018 Results assessing safety, pharmacokinetics, pharmacodynamics of BAY-1093884 in patients with Haemophilia A or B, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
    • 28 Nov 2018 According to a Bayer media release, data will be presented during Scientific Sessions at the 2018 American Society of Hematology (ASH) Annual Meeting.
    • 17 Oct 2018 Status changed from active, no longer recruiting to completed.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top